Bora Pharmaceuticals invests $10M to expand oral solid dose capabilities at two sites

The investment will expand operations over two years at facilities in Taiwan and Canada

The fast-growing contract development and manufacturing organisation (CDMO) provides services including clinical and commercial manufacturing, pharmaceutical development, packaging and serialisation, and analytical/microbiology testing. It has two facilities in Taiwan, located in Tainan and Zhunan, and one in Canada.    

Coinciding with the investment, Bora Mississauga relaunched a pilot facility that was purpose-built for development and clinical manufacturing and is separate from its commercial manufacturing activities.  

The facility has 25 flexible rooms which include misting showers and a separate air-handling unit to allow for clinical manufacturing of conventional and potent compounds at various batch sizes for oral solid dose as well as liquids, creams and ointments. 

The Mississauga site also acquired the Gerties MINI-PACTOR®, a laboratory roller compactor solution, which will be operational in the second quarter of 2022. 

In Zhunan, the company is set to commission a development / clinical area purpose built for containment. The space will allow Bora to safely handle High Potent Oral Solid Dose products categorized as OEB Level 4, <0.01 mg/m3. A new blister line will also be added to complement the current tablet and capsule packaging capabilities on site. 

Construction in Zhunan is expected to begin in Q2 2022, with operations planned for the first quarter of 2023.  

Bora CEO Bobby Sheng said the investments in Zhunan and Mississauga ‘really reinforce our company’s commitment to our facilities’ and are a ‘testament to the teams and talent pools we have there’. 

‘We now intend to invest further into our growth strategy and continue to be the best CDMO partner we can be,’ he said.